Skip to main content
. Author manuscript; available in PMC: 2012 Jul 12.
Published in final edited form as: Cancer Cell. 2011 Jul 12;20(1):66–78. doi: 10.1016/j.ccr.2011.06.010

Figure 7. Dot1l is required for transformation and maintenance of MLL-AF9 fusion driven leukemia in vivo.

Figure 7

(A) Survival curves for mice injected with 1×105 MLL-AF9 transformed lineage negative bone marrow cells 2–4 days after transduction with Cre or MIY-control retrovirus and resorting for GFP+/YFP+ cells.

(B) Survival curves for secondary recipient mice that received 1×105 MLL-AF9 leukemia cells isolated from leukemic mice that were subsequently transduced with Cre or MIY-control retrovirus 3 days prior to re-injection. Just prior to reinjection cells were resorted for GFP+/YFP+ cells.

See also Figure S7.